Biomarker ID | 863 |
PMID | 22315056 |
Year | 2012 |
Biomarker | sphingosine-1-phosphate (S1P) |
Biomarker Basis | Concentration Based (pmol/mg) |
Biomolecule | Protein |
Source | Plasma |
Subjects | Humans |
Regulation | Downregulated in Stage 2 PCa than Stage 1 PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Stage 1 Vs Stage 2 prostate cancer |
Type of Biomarker | Prognostic |
Cohort | Eighty-eight patients with localised, locally advanced, or metastatic PCa were recruited into study. Age-matched controls with benign prostate hyperplasia (BPH) (n = 110) with young healthy males with the very small chance of having PCa foci (n = 20) were included in this study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | S1P |